Christine Bellon Beam Therapeutics Inc. (BEAM) insider trading activity

Christine Bellon is Chief Legal Officer of Beam Therapeutics Inc.. Currently has a direct ownership of 117,294 shares of BEAM, which is worth approximately $2.29 Million. The most recent transaction as insider was on Apr 01, 2025, when has been sold 5,674 shares (Common Stock) at a price of $18.35 per share, resulting in proceeds of $104,117. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 117K

13.91% 3M change

12.14% 12M change

Total Value Held $2.29 Million

Christine Bellon Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 01 2025	SELL Open market or private sale	$104,117 $18.35 p/Share	5,674 Reduced 4.61%	117,294 Common Stock
Mar 31 2025	BUY Grant, award, or other acquisition	-	20,000 Added 13.99%	122,968 Common Stock
Feb 14 2025	SELL Open market or private sale	$340,000 $34.0 p/Share	10,000 Reduced 8.85%	102,968 Common Stock
Feb 14 2025	BUY Exercise of conversion of derivative security	$72,200 $7.22 p/Share	10,000 Added 8.13%	112,968 Common Stock
Jan 02 2025	SELL Open market or private sale	$30,627 $24.68 p/Share	1,241 Reduced 1.19%	102,968 Common Stock
Oct 01 2024	SELL Open market or private sale	$9,039 $23.48 p/Share	385 Reduced 0.37%	104,209 Common Stock
Apr 01 2024	SELL Open market or private sale	$109,240 $32.12 p/Share	3,401 Reduced 3.15%	104,594 Common Stock
Mar 31 2024	BUY Grant, award, or other acquisition	-	27,500 Added 20.3%	107,995 Common Stock
Jan 03 2024	SELL Open market or private sale	$50,382 $26.42 p/Share	1,907 Reduced 2.31%	80,495 Common Stock
Nov 20 2023	SELL Open market or private sale	$305,000 $30.5 p/Share	10,000 Reduced 10.82%	82,402 Common Stock
Nov 20 2023	BUY Exercise of conversion of derivative security	$72,200 $7.22 p/Share	10,000 Added 9.77%	92,402 Common Stock
Oct 02 2023	SELL Open market or private sale	$8,865 $22.85 p/Share	388 Reduced 0.47%	82,402 Common Stock
Apr 04 2023	SELL Open market or private sale	$33,773 $29.09 p/Share	1,161 Reduced 1.38%	82,790 Common Stock
Apr 03 2023	SELL Open market or private sale	$28,218 $30.31 p/Share	931 Reduced 1.1%	83,951 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	17,500 Added 17.09%	84,882 Common Stock
Mar 30 2023	BUY Exercise of conversion of derivative security	$64,554 $7.22 p/Share	8,941 Added 11.71%	67,382 Common Stock

Christine Bellon

Chief Legal Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BEAM shares.

Notify only if

Value

Insider Trading

Get notified when an Beam Therapeutics Inc. insider buys or sells BEAM shares.

Notify only if

Operation

Value

Type

News

Receive news related to Beam Therapeutics Inc.

Track Activities on BEAM

Account